Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02125084 · ClinicalTrials.gov registry record · Phase 1
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02125084 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 38 participants.
The verdict
NCT02125084, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of a novel combination of agents, enzalutamide and everolimus, for the treatment of patients with metastatic castrate-resistant prostate cancer who have never received prior chemotherapy, or who have previously received docetaxel chemotherapy and have progressive disease.
Interventions
- DRUG Everolimus
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-10 |
| Est. Completion | 2021-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02125084
The ClinicalTrials.gov registry entry for NCT02125084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT02125084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02125084 about?
NCT02125084 is a clinical study titled "Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer". The purpose of this study is to determine the safety and efficacy of a novel combination of agents, enzalutamide and everolimus, for the treatment of patients with metastatic castrate-resistant prostate cancer who have never received prior chemotherapy, or who have previously received docetaxel chem...
What is the current status of trial NCT02125084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2014-10. Estimated completion is 2021-05-03.
What interventions are being tested in trial NCT02125084?
The interventions under investigation include: Everolimus (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02125084?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.